AOAthanasios Oikonomou

Athanasios Oikonomou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Athanasios Oikonomou has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Generalised Epigenetic Clock Reveals Therapeutic Vulnerabilities Linked to Ageing in Cancer Cells

    by Irene Fernandez-Rebollo, Alessandro Digilio, Athanasios Oikonomou, Lucia Trastulla, Manel Esteller, Francesco Iorio

    Epigenetic clocks estimate biological age from DNA methylation patterns but perform poorly in cancer due to extensive epigenetic reprogramming, limiting the study of ageing in tumour biology.Here, we develop GepiClock, an epigenetic clock trained on DNA methylation data from 32 cancer types in The Cancer Genome Atlas. Based on 4,862 CpG sites, GepiClock accurately predicts age across both tumour and normal samples, indicating that core ageing-associatedmethylation programmes remain detectable despite malignant transformation.Applying GepiClock to molecularly profiled cancer cell lines with matched drug response and CRISPR screening data revealed age-associated vulnerabilities. Younger-predicted cell lines were more sensitive to mTOR, MEK1/2 and HSP90 inhibitors, whereas older lines showed increased sensitivity to AKT and PI3Kα inhibitors. Additional cancer-type-specific patterns and age-associated genetic dependencies were identified.These findings establish a framework to quantify biological age in cancer and link ageing-associated states to therapeutic vulnerabilities.

  • Open Access

    CRISPR-enhanced assessment of variants of unknown significance nominates oncology therapeutic targets and drug repositioning opportunities

    by Aurora Savino, Athanasios Oikonomou, Riccardo R De Lucia, Miguel L Grau, Kathrina McCarten, Hanna Najgebauer, Umberto Perron, Luca Azzolin, Alexandra Livanova, Paolo Cremaschi, et al.

    Identifying cancer driver genes and mutations remains a cornerstone of cancer research and a prerequisite for developing effective targeted therapies. While current approaches have successfully uncovered recurrent oncogenic alterations, they often miss rare or context specific events, leaving large segments of the mutational landscape of human cancers functionally uncharacterised. We developed a CRISPR enhanced analytical framework that systematically identifies Dependency-Associated Mutations (DAMs): somatic variants linked to increased viability dependency on their hosting gene in cancer cells. To this aim, we designed a rank based metric applicable even to singleton variants and analysed large scale functional genomics data from over a thousand cancer cell lines. We discovered more than 2,000 DAMs, involving more than 1,000 in genes not previously reported as cancer drivers. These unreported DAM bearing genes reinforce canonical oncogenic pathways, revealing overlooked but functionally coherent nodes. By integrating drug response profiles, patient mutation data, and functional impact predictions, we distilled these findings into a refined set of hundreds high priority DAMs: variants that are not only functionally impactful and recurrent in tumours, but also encode druggable proteins and exhibit strong potential for clinical translation. Comparative analyses revealed significant overlap with an independent study, underscoring the robustness and reproducibility of our approach. All results are available through the CRISPR VUS Portal ( https://vus-portal.fht.org ), an interactive resource for exploring mutation dependency relationships across cancer-types. Our findings expand the functional and therapeutic landscape of cancer genomics, providing a scalable framework to interpret non recurrent variants and systematically uncover novel cancer vulnerabilities. By linking mutational profiles to gene essentiality and pharmacological sensitivity, our work extends the reach of precision oncology beyond canonical cancer drivers.

  • Open Access

    Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening

    by Athanasios Oikonomou, Titus Watrin, Luigia Valsecchi, Katerina Scharov, Angela Maria Savino, Julian Schliehe-Diecks, Michela Bardini, Grazia Fazio, Silvia Bresolin, Andrea Biondi, et al.


  • Open Access

    High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia

    by Athanasios Oikonomou, Luigia Valsecchi, Manuel Quadri, Titus Watrin, Katerina Scharov, Simona Procopio, Jia-Wey Tu, Melina Vogt, Angela Maria Savino, Daniela Silvestri, et al.